Moreover, the tumor-penetrating peptide iRGD and the ROS-responsive nanoparticles were co-administered to further enhance the delivery efficiency of siFGL1 and siPD-L1, thereby significantly reducing the protein levels of FGL1 and PD-L1 in tumor cells. The gene discussed is CD274; the disease is neoplasm.